Back

PRIME Education, Inc. (PRIME®)

  • Glomerulonephritis, IGA

New and Emerging Therapies in IgA Nephropathy: Latest Data and Clinical Implications

Advances in the understanding of IgA nephropathy (IgAN) pathophysiology have ushered in a wave of targeted therapies with the potential to transform personalized care. Tune in to the second webcast of this two-part TheraTalk series to examine the pathophysiologic mechanisms and latest clinical evidence behind these therapies. Drawing on real-world insights from a national survey of nephrologists, two leading IgAN experts deliver practical, evidence-based guidance on differentiating available and emerging therapies to support individualized, patient-centered treatment decisions. This session also features a short animation illustrating the key drivers of IgAN progression and key therapeutic targets, as well as a case-based discussion on developing individualized IgAN treatment plans.

Credit & MOC Details

Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.

Credit types

IPCE CreditsUp to 1 creditAAPA Category 1 Credit™Up to 1 creditAMA PRA Category 1 Credit™Up to 1 creditNursingUp to 1 creditPharmacyUp to 1 credit

MOC types

ABIM — Medical KnowledgeUp to 1 point

FDA REMS

No

Qualifies for MIPS

No

Pricing

Free

Reported to ACCME by the provider

  • Case-based learning
  • includes On-demand / recorded video
  • Credit · Up to 1 credit
  • MOC · Up to 1 point
  • Commercial Support
  • Released
    Jul 31, 2026
  • Last day to claim credit
    Jul 31, 2027 10 months left